Introduction
============

After the first case reports, open studies, and preliminary reviews on the efficacy of botulinum toxin in pain therapy, the use of this substance for the treatment of headache disorders has been discussed widely ([@b15-ndt-3-761]; [@b1-ndt-3-761]; [@b4-ndt-3-761]; [@b8-ndt-3-761]; [@b2-ndt-3-761]). However, the interpretations of the findings in trials and case series are conflicting and inconsistent. In this paper, the published evidence based on the placebo-controlled, double-blind trials for the prophylaxis of chronic daily headache with botulinum toxin A will be analysed. This analysis is based on literature research in medical databases (Medline, Embase, Current Contents, Science Citation Index) from 1995 to 2007 and on published congress reports of the relevant headache and pain congresses. Key words were botulinum and chronic headache.

Chronic daily headache is defined as headache occurring on at least 15 days per month for at least three months and with a daily duration of at least four hours a day ([@b24-ndt-3-761]). Per definition and per classification of the IHS, the following four entities are differentiated: chronic migraine, chronic tension-type headache, hemicrania continua and new onset daily persistent headache. These types can occur with and without medication overuse. This means that medication overuse headache is not separately considered in the classification system of chronic daily headache.

Only studies on the prophylactic treatment of headache were considered. As recommended by the International Headache Society (IHS), headache frequency was regarded the most important primary endpoint ([@b22-ndt-3-761]; [@b29-ndt-3-761]). The diagnosis of cervicogenic headache and studies on patients with different coexisting or with other headache diagnoses were not considered.

Trials on headache treatment
============================

In [Table 1](#t1-ndt-3-761){ref-type="table"}, the studies on botulinum toxin in the prophylactic treatment of chronic tension-type headache (one trial also with episodic tension-type headache) according to the IHS criteria are listed. Ten randomized, double-blind, and placebo-controlled studies on patients suffering from tension-type headache were included ([@b10-ndt-3-761]; [@b27-ndt-3-761]; [@b20-ndt-3-761]; [@b3-ndt-3-761]; [@b21-ndt-3-761]; [@b23-ndt-3-761]; [@b14-ndt-3-761]; [@b18-ndt-3-761]; [@b7-ndt-3-761]; [@b26-ndt-3-761]). Apart from one, all these studies were negative for the primary endpoint and did not show any efficacy of botulinum toxin in reduction of headache frequency or intensity. The only study with a significant reduction of headache days in the treatment group but not in the placebo group, however, did not perform a formal statistical comparison between the two groups ([@b27-ndt-3-761]). In one long-term blinded and placebo-controlled study, the efficacy of botulinum toxin was maintained over a year in some patients ([@b19-ndt-3-761]). In some secondary endpoints such as headache intensity or headache duration, a positive trend or significant subgroup analysis could be observed. In particular, patients with mixed headache and migrainous headache showed benefit. The studies used different doses (25 to over 100 IU Botox^®^ and up to 240 IU Dysport^®^) and injection sites making a direct comparison difficult. The design of these studies mainly followed the guidelines of the IHS for studies on tension-type headache ([@b22-ndt-3-761]) including the diagnosis according to the first ([@b11-ndt-3-761]) and the second ([@b12-ndt-3-761]) version of the IHS criteria for chronic tension-type headache (dull, bilateral, moderate headache on more than 15 days per month).

In summary, all but one randomized, double-blind, and placebo-controlled studies on botulinum toxin in the prophylactic treatment of chronic tension-type headache showed negative results for the primary endpoint.

In unspecific chronic daily headache, very recently larger studies have been performed since it has been suggested from observational studies that these patients might show the most benefit from botulinum toxin. The randomized, double-blind, and placebo-controlled studies on this headache type are listed in [Table 2](#t2-ndt-3-761){ref-type="table"}. Three different studies ([@b17-ndt-3-761]; [@b25-ndt-3-761]; [@b16-ndt-3-761]; [@b9-ndt-3-761]) showed a negative result for the primary endpoint. However, preplanned subgroup analyses of one study ([@b16-ndt-3-761]) showed significant improvements for patients with no other prophylactic treatment and for patients with chronic migraine with or without medication overuse ([@b5-ndt-3-761]; [@b6-ndt-3-761]).

There are no published controlled trials on the use of botulinum toxin A in the treatment of hemicrania continua and of new onset daily persistent headache.

Conclusion
==========

In this review, the current published data on botulinum toxin in the treatment of chronic daily headache was analysed regarding all published double-blind and placebo-controlled trials. This analysis showed that a general efficacy of this therapy cannot be postulated to date. After a period of very optimistic case series and open studies, we are now able to analyse placebo-controlled and double-blind studies. This evidence-based approach gives us a more pessimistic picture showing no consistent efficacy of botulinum toxin in idiopathic headache disorders. For chronic tension-type headache, nearly all randomized, double-blind, placebo-controlled trials showed negative results. In summary, pure idiopathic headache disorders cannot be regarded as an indication for botulinum toxin to date.

For chronic daily headache, no consistent results can be obtained from randomized, double-blind, and placebo-controlled trials. However, analysing subgroups of these studies enables the identification of patients who might benefit from botulinum toxin. It is likely that those patients with chronic daily headache (with or without medication oversue) who are severely impaired (ie, highest loss of productivity) and who are not receiving any other prophylactic treatment are the appropriate group of patients with a benefit from botulinum toxin. Since this total patient group shows a prevalence of up to 4% in population based epidemiological studies ([@b28-ndt-3-761]), it is warranted to further elucidate the clinical efficacy of botulinum toxin in this subgroup. In this context it should be noted that a subgroup of patients with exploding headache quality (in contrast to imploding or ocular headache quality) showed a good response to botulinum toxin suggesting that allodynia is an important predictor for the probability that botulinum toxin is efficacious ([@b13-ndt-3-761]).

###### 

Randomized, double-blind, placebo-controlled studies on botulinum toxin in the prophylactic treatment of tension-type headache

  Reference          Indication to treatment                       Number of patients   Results compared with placebo
  ------------------ --------------------------------------------- -------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [@b10-ndt-3-761]   chronic tension-type headache                 10                   No significant reduction of pain intensity, headache hours, or use of analgesics
  [@b27-ndt-3-761]   chronic tension-type headache                 41                   Significant reduction of headache intensity and pain-free days in month 3 compared with baseline data in group with botulinum toxin but not in placebo group
  [@b20-ndt-3-761]   chronic tension-type headache                 21                   No significant differences between botulinum toxin and placebo in all headache parameters
  [@b3-ndt-3-761]    episodic and chronic tension- type headache   41                   No significant difference in headache frequency
  [@b21-ndt-3-761]   chronic tension-type headache                 59                   No significant differences between botulinum toxin and placebo in all headache parameters
  [@b23-ndt-3-761]   chronic tension-type headache                 113                  No significant reduction in all efficacy endpoints
  Ka et al 2004      chronic tension-type headache                 40                   No significant reduction of headache frequency; significant reduction of pain intensity
  [@b18-ndt-3-761]   chronic tension-type headache                 40                   No significant results
  [@b7-ndt-3-761]    chronic tension-type headache                 125                  No significant results
  [@b26-ndt-3-761]   chronic tension-type headache                 300                  No significant difference in headache frequency (primary endpoint) for all treatment groups (treatment with 150 U was significantly inferior to placebo); significant increase in percentage of responders for three treatment groups

###### 

Randomized, double-blind, placebo-controlled studies on botulinum toxin in the prophylactic treatment of chronic daily headache

  Reference          Indication to treatment   Number of patients   Results compared with placebo
  ------------------ ------------------------- -------------------- -------------------------------------------------------------------------------------------------------------------------------------------------
  [@b17-ndt-3-761]   chronic daily headache    60                   No significant reduction but trend (p = 0.07) in primary endpoint (days with headache)
  [@b25-ndt-3-761]   chronic daily headache    702                  No significant reduction of headache frequency
  [@b16-ndt-3-761]   chronic daily headache    355                  Primary endpoint (reduction of headache free days) negative; secondary endpoint(percentage of patients with reduction \>50%) positive
  [@b5-ndt-3-761]    chronic daily headache    228                  Significant reduction of headache frequency in patients not receiving other prophylactic drugs (subanalysis of [@b16-ndt-3-761])
  [@b6-ndt-3-761]    chronic migraine          355                  Significant reduction of migraine frequency for all treatment arms (105--260 U Botox®) as compared to placebo (subanalysis of [@b16-ndt-3-761])
  [@b9-ndt-3-761]    chronic migraine          60                   No significant reduction in migraine days (p=0.18)
